The use of febuxostat in comorbid patients with gout in real clinical practice: own data
Objective: to evaluate the efficacy and safety of febuxostat (Azuriks®) in the treatment of patients with gout and concomitant diseases.Patients and methods. An observational, open-label, single-centre study of the results of febuxostat use in 85 gout patients with insufficient prior allopurinol eff...
Main Authors: | E. V. Zonova, D. N. Orlov, A. S. Kabargina |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2022-06-01
|
Series: | Современная ревматология |
Subjects: | |
Online Access: | https://mrj.ima-press.net/mrj/article/view/1301 |
Similar Items
-
The place of febuxostat in the treatment of gout
by: A. M. Novikova, et al.
Published: (2020-09-01) -
Febuxostat in the therapy of gout: from theory to practice
by: E. V. Ilyinykh, et al.
Published: (2018-01-01) -
Microbiota as a new pathogenetic factor in the development of chronic hyperuricemia and gout. Part 2: gout therapy and the gut microbiota
by: M. S. Eliseev, et al.
Published: (2022-12-01) -
The Experience of Using a Combination of Febuxostat and Canakinumab in Tophaceous Gout Complicated by Chronic Kidney Disease in a Teenage Patient: A Case Study
by: Maria I. Kaleda, et al.
Published: (2018-12-01) -
Urate-lowering therapy for heart failure
by: O. V. Zhelyabina, et al.
Published: (2019-09-01)